Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | AR | P10275 | 9/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11153594 | 0.85 | NPC1 (0.60) | NPC1KDM4EUSP2ALDH1A1GAA | |
| SCHEMBL1511834 | 0.84 | ALDH1A1 (0.60) | NPC1KDM4EUSP2ALDH1A1AR | |
| SCHEMBL8777864 | 0.82 | ALDH1A1 (0.58) | KDM4EUSP2ALDH1A1GAAAR | |
| SCHEMBL7810421 | 0.81 | NPC1 (0.60) | NPC1ALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL11411334 | 0.81 | ALDH1A1 (0.56) | KDM4EUSP2ALDH1A1GAAAR | |
| SCHEMBL1981958 | 0.79 | KDM4E (0.55) | KDM4EUSP2ALDH1A1GAAAR | |
| SCHEMBL14421871 | 0.79 | AR (0.47) | KDM4EUSP2ALDH1A1ARCHEK1 | |
| SCHEMBL2579594 | 0.78 | ALDH1A1 (0.44) | KDM4EUSP2ALDH1A1ARIMPDH2 | |
| SCHEMBL29559694 | 0.78 | KDM4E (0.53) | KDM4EUSP2ALDH1A1ARIMPDH2 | |
| SCHEMBL3344289 | 0.78 | ALDH1A1 (0.53) | NPC1KDM4EUSP2ALDH1A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0303573-B1 | PYRROLIDINE-2,5 DIONES AND 4,5,6,7-TETRAHYDROISO-INDOLE-1,3 DIONES | CIBA-GEIGY AG (CH) | 1993-06-09 | — | — | EP | claimed |
| EP-2007767-B1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS R&D LTD (GB) | 2011-11-02 | — | — | EP | disclosed |
| EP-2007767-B1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS R&D LTD (GB) | 2011-11-02 | — | — | EP | disclosed |
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | VERNALIS (R&D) LTD. (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | VERNALIS (R&D) LTD. (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | VERNALIS (R&D) LTD. (GB) | 2009-06-25 | — | — | US | disclosed |
| WO-2009030871-A1 | PYRROLOPYRIMIDINE DERIVATIVES HAVING HSP90 INHIBITORY ACTIVITY | VERNALIS R & D LTD (GB) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009030871-A1 | PYRROLOPYRIMIDINE DERIVATIVES HAVING HSP90 INHIBITORY ACTIVITY | VERNALIS R & D LTD (GB) | 2009-03-12 | — | — | WO | disclosed |
| EP-2007767-A1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS (R&D) LTD (GB) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007104944-A1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS (R & D) LTD. (GB) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007104944-A1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS (R & D) LTD. (GB) | 2007-09-20 | — | — | WO | disclosed |
| US-5492919-A | IRRITABLE BOWEL DISORDER | SMITHKLINE BEECHAM P.L.C. (GB) | 1996-02-20 | — | — | US | disclosed |
| EP-0596933-A1 | 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-05-18 | — | — | EP | disclosed |
| EP-0303573-B1 | PYRROLIDINE-2,5 DIONES AND 4,5,6,7-TETRAHYDROISO-INDOLE-1,3 DIONES | CIBA-GEIGY AG (CH) | 1993-06-09 | — | — | EP | disclosed |
| WO-1993002677-A1 | 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | HSP90AA1, HSP90AB1, RAF1 | NPC1 3832/4885KDM4E 3672/4885USP2 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.